School of Pharmacy
University of Wisconsin-Madison

Louis W. Busse Lecture Series

About Dr. Louis W. Busse

Dr. Louis W. Busse, a native of Wisconsin, received a BA degree from Lawrence College in 1934, a BS in Pharmacy from the University of Wisconsin in 1936, and a PhD in Pharmacy from the same institution in 1940. Except for one year as Drug Analyst with the War Production Board in Washington, D.C., during World War II, his entire career was spent at the University of Wisconsin School of Pharmacy. From 1954 -68 he served as Associate Dean, and from 1956-66 he was coordinator of Extension Services. He retired from the UW Faculty in 1978 as the Edward Kremers Professor of Pharmacy.

During his career, Professor Busse was a leader in the development of pharmaceutical research, continuing education, and pharmacy internship. He was a primary developer of the Land O’Lakes Industrial Research Conferences, patterned after the Gordon Research Conferences. The first Land O’Lakes conference was held in 1959. Dr. Busse’s early research interests were in powder technology and its application to pharmaceutical tableting, including the development of the instrumented tablet press.

Professor Busse was recognized with many awards and honors. In 1951 he received the APhA Ebert Prize. In 1967 he received the APhA Foundation Achievement Award for the Advancement of Pharmacy, while in 1974 he served as the president of the Academy of Pharmaceutical Sciences. He served on the Board of Trustees of the U.S.P. from 1975 to 1980.

Through many contributions to his school, his profession, and to pharmaceutical research, Professor Busse had a significant impact on the quality of pharmacy research in the pharmaceutical industry. Upon his retirement the Louis W. Busse Lecture Series was established. The lectureship brings an outstanding industrial pharmaceutical scientist to the School of Pharmacy annually.

Named Lecture Series

Past Busse Lectures

This is an accordion element with a series of buttons that open and close related content panels.

Feb 16, 2024: Kam W. Leong, PhD

Kam W. Leong, PhD
Professor, Dept. of Biomedical Engineering
Columbia University

  • Targeting Nucleic Acids to Combat Inflammation: A New Therapeutic Strategy

April 28, 2023: Samir Mitragotri, PhD

Samir Mitragotri, PhD
Professor and Chair, Dept. of Biomedical Engineering
Harvard University

  • A Hitchhiker’s and Backpacker’s Perspective on Drug Delivery

April 8, 2022: Aliasger K. Salem, PhD, FAAPS, FAIMBE

Aliasger K. Salem, PhD, FAAPS, FAIMBE
Professor, Dept. of Pharmaceutical Sciences
University of Iowa College of Pharmacy

  • Biodegradable Particles for Vaccine Delivery

April 8-9, 2021: James R. Baker, Jr., MD

James R. Baker, Jr., MD
Professor Emeritus
Dept. of Internal Medicine and Dept. of Biomedical Engineering
University of Michigan

  • Polymer Targeted Therapeutics: Learning from Our Failures
  • Manipulating the Immune System for Therapeutic Benefit

March 28-29, 2019: Dale Wurster, PhD

Dale Wurster, PhD
Professor, Department of Pharmaceutical Sciences and Experimental
University of Iowa College of Pharmacy

  • Determination of Adsorption Site Specificity – Activated Carbon as a Model
  • Compression Calorimetry

May 4, 2018: Dr. Simon J.L. Billinge

Dr. Simon J.L. Billinge
Professor of Materials Science and of Applied Mathematics
Columbia University
Physicist, Brookhaven National Laboratory

  • Amorphous or nanocrystalline? Advances in total scattering pair distribution function methods for characterizing amorphous and nanocrystalline pharmaceuticals
  • Finding atoms at the nanoscale for more controlled drug delivery

Sept 14-15, 2017: Dr. Allen S. Hoffman

Dr. Allen S. Hoffman
Professor Emeritus
Department of Bioengineering
University of Washington, Seattle

  • Update on PEG and PEGylation
  • History of Biomaterials & Medical Devices

Apr 8, 2016: Dr. Mauro Ferrari, PhD

Dr. Mauro Ferrari, PhD
President and CEO, Houston Methodist Research Institute
Director, Institute for Academic Medicine, Houston Methodist Hospital System
Senior Associate Dean & Professor of Medicine, Weill Cornell Medical College

  • Nanomedicine 101 & 102
  • Transport Oncophysics

Apr 30 – May 1, 2015: Dr. Kazunori Kataoka

Dr. Kazunori Kataoka
Professor of Biomaterials, Graduate School of Engineering
University of Tokyo

  • Nanotechnology to Develop “the Magic Bullet” for Targeted Cancer Therapy
  • Targeted Chemo- and Molecular-Therapy by self-Asssembled Supramolecular Smart (SSS) Nanosystems from Funcitonalized Block Copolymers

Dec 12-13, 2013: Dr. Leslie Z. Benet

Dr. Leslie Z. Benet
Professor, Department of Bioengineering & Therapeutic Sciences
Schools of Pharmacy & Medicine – UC-San Francisco

  • Transporters, Enzymes and Transporter-Enzyme Interplay in Predicting Drug Absorption and Disposition
  • A Unifying PK/PD Relationship to Predict Drug Dosing REgimens for NMEs, Validate clinical Biomarkers as Qualified Surrogates and Serve as a Quality PK/PD Model Metric

May 9-10, 2013: Dr. Gordon L. Amidon

Dr. Gordon L. Amidon
Charles R. Walgreen, Jr., Professor of Pharmacy
Professor of Pharmaceutical Sciences
College of Pharmacy, University of Michigan

  • A Century of Conflation, Confusion and Global Warming: Biopharmaceutical Product Standards
  • Improving the Oral Absorption of BCS Class III and IV Drugs

Dec 1-2, 2011: Dr. Donald A. Tomalia

Dr. Donald A. Tomalia
CEO and Founder NanoSynthons, LLC
National Dendrimer & Nanotechnology Center, Mount Pleasant, Michigan

  • Dendrimer-based Drug Delivery, Imaging and nanopharmaceuticals
  • Dentron/Dendrimers: Windo to a New Systematic Framework for Unifying Neuroscience

Oct 7-8, 2010: Dr. James M. Anderson

Dr. James M. Anderson
Department of Pathology
Case Western Reserve University

  • Inflammatory Cell Interactions and the Foreign Body Reaction with Surface-Modified Biomaterials
  • Biomaterial Biocompatibility and Biological Design Criteria: Issues and Perspectives

Oct 22-23, 2009: Dr. Valentino J. Stella

Dr. Valentino J. Stella
Distinguished Professor of Pharmaceutical Chemistry
University of Kansas

  • A Case for Prodrugs
  • Drug Release of a Poorly Water Soluble Drug from Microporous Pump Tablets and Pellets with (SBE)TM-β-CD as Both a Soubizer and Osmoagent?

Nov 13-14, 2008: Dr. Kinam Park

Dr. Kinam Park
Showalter Distinguished Professor of Pharmaceutics
Purdue University

  • Drug Delivery Systems: Macro Issues of Nano/Micro Formulations
  • Drug-eluding Stents: What Now?

Nov 8-9, 2007: Dr. Ronald T. Borchardt

Dr. Ronald T. Borchardt
Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry
The University of Kansas

  • Drug Design with Biopharmaceutics in Mind: A Paradigm Shift in Drug Discovery
  • The Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier

Nov 30-Dec 1, 2006: Dr. Allan S. Myerson

Dr. Allan S. Myerson
Philip Danforth Amour Professor of Engineering
Provost & Senior Vice President, Illinois Institute of Technology

  • Crystallization Process Development in the Pharmaceutical Industry
  • Nucleation Mechanism and Its Role in the Polymorphic Outcome of Solution Crystallization

May 18-19, 2006: Dr. Jindrich “Henry” Kopecek

Dr. Jindrich “Henry” Kopecek
Distinguished Professor of Bioengineering
Distinguished Professor of Pharmaceutics & Pharmaceutical Chemistry, Department of Bioengineering
University of Utah

  • Water-soluble Polymers for Cancer Therapy: Concept, Clinical Applications, and Future Directions
  • Self-assembly of Graft and Block Copolymers into Stimuli-sensitive Hydrogels

Apr 7-8, 2005: Dr. Stephen R. Byrn

Dr. Stephen R. Byrn
Charles B. Jordan Professor of Medicinal Chemistry
Purdue University

  • Solid State Pharmaceutical Chemistry
  • The Regulated Pharmaceutical Industry in 2010

Apr 8-9, 2004: Dr. Arthur J. Coury

Dr. Arthur J. Coury
Vice President of Biomaterials Research
Genzyme Corp

  • Sustained Drug Delivery: Advanced Systems, Growing Therapeutic Applications
  • A Biomaterials Career Regrospective: 1976-2004

Oct 17-18, 2002: Prof. C. Russell Middaugh

Prof. C. Russell Middaugh
Aya & Takeru Higuchi Distinguished Professor of Pharmaceutical Chemistry
Department of Pharmaceutical Chemistry
University of Kansas

  • Stabilizing Vaccines for the Developing World
  • The Polyanion World Hypothesis

Oct 10-11, 2001: Dr. Arthur R. Mlodozeniec

Dr. Arthur R. Mlodozeniec
Principal Scientist, TechniPharm Consulting Group
Menlo Park, CA

  • The Formulation and Pharmaceutical Develpoment of Haloperoxidase Enzymes as Hybrid Products for Microbicidal Activity – Physical and Analytical Chemistry and Pharmaceutics
  • Microbicidal Activity and Topical Drug Delivery for Vaginal Microbicides and Surgical & Combat Wounds – Pharmaceutical Control and Stability

Sept 23, 24, 1999: Dr. James L. Wright

Dr. James L. Wright
Vice President of Pharmaceutical Development
Alkermes Inc., Cambridge, MA

  • Using Injectable Drug Delivery Systems to Iimprove the Treatment of Patients
  • The Effect of Protein Particle Size on Drug Delivery

May 6-7, 1998: Dr. Sung Wan Kim

Dr. Sung Wan Kim
Professor of Pharmaceutics
Director of the Center for Chemical Delivery Systems
University of Utah

  • Novel Polymers for the Delivery of Macromolecular Drugs and Cells
  • New Polymeric Gene Carriers

Feb 5-7. 1997: Dr. Douwe D. Breimer

Dr. Douwe D. Breimer
Professor of Pharmacology & Therapeutics, Leiden University, Netherlands
Director of Research, The Leiden/Amsterdam Center for Drug Research

  • Drug Transport across the Blood-Brain Barrier
  • Pharmacodynamics of Rate and Time Control in Drug Delivery

Feb 7-8, 1996: Dr. Joseph D. Andrade, Jr.

Dr. Joseph D. Andrade, Jr.
Professor
Department of Bioengineering, Materials Science, & Engineering and Department of Pharmaceutics
College of Pharmacy, University of Utah

  • Direct Reading Biosensors: Analytical Chemistry without Instruments
  • Scientists and the Public Understanding of Science

May 3-4, 1994: Dr. William J. Curatolo

Dr. William J. Curatolo
Manager, Oral Druge Delivery and Controlled Release Groups
Pfizer Central Research Division

  • Intestinal Permeability Enhancement for Poorly Permeable Drugs: Efficacy and Toxicity
  • Oral Bioavailability Improvement Strategies for Tripeptide Renin Inhibitors

Apr 19, 1993: Dr. Lewis J. Leeson

Dr. Lewis J. Leeson
Distinguished Research Fellow
CIBA-GEIGY Pharmaceuticals

  • Generic Substitution in New Jersey – A New Jersey Drug Utilization Rreview Council Report
  • A Bit of Physical Pharmacy Nostalgia – The Ionization of Tetracyclines

Oct 23-24, 1991: Dr. Elizabeth B. Vadas

Dr. Elizabeth B. Vadas
Director, Pharmaceutical Research & Development
Merck-Frosst Center for Therapeutic Research

  • The Development of a New Therapeutic Entity: The Search for New Therapies in Respiratory Disease
  • Formulation Development and Bioanalytical Evaluation of MK-886, an Orally Active Leukotriene Biosynthesis Inhibitor

Apr 15-16, 1991: Dr. Robert Langer

Dr. Robert Langer
Kenneth J. Germeshausen Professor of Chemical and Biochemical Engineering
Massachusetts Institute of Technology

  • Immobilized Enzyme Bioreactors for Removal of Heparin, Bilirubin, and cholesterol
  • Novel Polymeric Delivery Systems for Drugs and Mammalian Cells

Nov 28-29, 1989: Dr. Felix Franks

Dr. Felix Franks
Director of the Biopreservation Division
Pafra Ltd.

  • Cold Resistance in Living Organisms: What Can We Learn from Nature?
  • The In Vitro Stabilization of Proteins: Science, Engineering, Legislation and Economics

Apr 5-6, 1988: Dr. Russell O. Potts

Dr. Russell O. Potts
Manager of the Dermally Applied Drugs (DAD) Group
Pfizer Central Research

  • Statum Corneum Lipids and Skinn Barrier Function: In Vitro and In Vivo Effects
  • Can Epidermal Metabolism Affect Topical Drug Delivery?

Apr 28-29, 1987: Dr. Richard E. Jones

Dr. Richard E. Jones
Director of Pharmaceutical Research and Development
Genentech, Inc.

  • Design and Development of Protein Pharmaceuticals
  • Preformulation Characterization of Recombinant Tissue-Type Plasminogen Activator (rt-PA)

Apr 22-23, 1986: Dr. Francis C. Szoka, Jr.

Dr. Francis C. Szoka, Jr.
Associate Professor of Pharmacy and Pharmaceutical Chemistry
School of Pharmacy, UC-San Francisco

  • The Role of Bilayer Contact in Membrane Destabilization: Applications to Drug Delivery from pH Sensitive Liposomes
  • The Magic Bullet Revisted – Targeting of Drugs Using Drug Carriers

Apr 22-23, 1985: Dr. Takeru Higuchi

Dr. Takeru Higuchi
University Regents Professor
School of Pharmacy, University of Kansas

  • Drug Absorption Across the Skin
  • Solubility of Organic Compounds

May 3-4, 1984: Dr. William R. Good

Dr. William R. Good
Director, Basic Pharmaceutics Research, Pharmaceuticals Division
CIBA-GEIGY Corporation

  • Pharmaceutics – An Interdisciplinary Discipline
  • Transdermal Drug Delivery – Opportunities in Endocrinology

Feb 21-22, 1983: Dr. Michael J. Pikal

Dr. Michael J. Pikal
Research Scientist, Lilly Research Laboratories
Division of Eli Lilly and Company

  • Industrial Pharmaceutical Research: Scientific Solutions to Practical Problems
  • Heat and Mass Transfer in the Freeze Drying of Pharmaceuticals

Nov 12-13, 1981: Dr. Felix Theeuwes

Dr. Felix Theeuwes
Vice President, Product Research and Development
Alza Corporation

  • The Development of Osmotic Pumps
  • Osmotic Pumps as Rate Specified Dosage Forms

Nov 3-5, 1980: Dr. K. C. Kwan

Dr. K. C. Kwan
Senior Director, Merck Dohme Research Laboratories

  • Physiological Disposition of Sulindac
  • Drug Interaction as a Pharmacokinetic Tool
  • Methods and Assumptions in Bioavailability Evaluation

Oct 1-3, 1979: Dr. Everett N. Hiestand

Dr. Everett N. Hiestand
Senior Scientist
The Upjohn Company

  • Material Properties That Influence Tableting
  • Time Dependent Properties in Tableting
  • Applications of Powder Flow and Compaction Theory to Tablet Machines